PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES

• Kim Linton,
• Francesco Forconi,
• David Lewis,
• John Riches,
• Dima El-Sharkawi,
• Mary Gleeson,
• Sarah G Injac,
• Srinand Nandakumar,
• May Tan,
• Ganesh Cherala,
• Graham P Collins

Affiliations

Kim Linton

1 Manchester Cancer Research Centre, Division of Cancer Sciences, Manchester, United Kingdom

Francesco Forconi

2 University Hospital Southampton NHS Trust, Southampton, United Kingdom

David Lewis

3 Derriford Hospital, Plymouth, United Kingdom

John Riches

4 Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Dima El-Sharkawi

5 Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Mary Gleeson

6 Sarah Cannon Research Institute, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

Sarah G Injac

7 Nurix Therapeutics, Inc., San Francisco, United States

Srinand Nandakumar

8 Nurix Therapeutics, Inc., San Francisco, United States

May Tan

7 Nurix Therapeutics, Inc., San Francisco, United States

Ganesh Cherala

7 Nurix Therapeutics, Inc., San Francisco, United States

Graham P Collins

9 Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom